ClinicalTrials.gg

Program

DW4421

A development code. Also written as “DW4421 20mg”, “DW4421 40mg” and “DW4421-T1”.

Its studies are mostly in Gastroesophageal Reflux, led by Daewon Pharmaceutical.

Furthest: phase 3, since Oct 23, 20266 company-led studies, 4 open or running

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Daewon Pharmaceutical64 open or runningphase 3since Oct 23, 2026Dec 22, 2025none ahead

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Dec 22, 2025First studies: 2 phase 1 studiesFirst studyNCT07364838, NCT07343245
  2. Jan 6, 20263 phase 1 studiesNCT07364877, NCT07364851, NCT07382661
  3. Oct 23, 2026Phase 3 study in Gastroesophageal RefluxPhase 3 reachedNCT07931521 · 328 enrolled · South Korea

TargetBeta

Not stated by its company or a source we have read. Most early programs say nothing of it.

Studies

All 6 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT07931521Gastroesophageal Reflux · South Korea3CompletedAug 31, 2026328
NCT07382661Healthy Adult Volunteers · South Korea1Not yet recruitingMay 202636
NCT07364877Healthy Adult Volunteer · South Korea1By invitationMar 19, 202638
NCT07364851Healthy Adult Volunteer · South Korea1Not yet recruitingMay 30, 202638
NCT07364838Gastroesophageal Reflux · South Korea1CompletedApr 8, 202524
NCT07343245Healthy Adult · South Korea1RecruitingFeb 22, 2026150

How it is read

Names in the registry

  • “DW4421”, 4 entries
  • “DW4421 20mg”, 1 entry
  • “DW4421 40mg”, 1 entry
  • “DW4421-T1”, 1 entry

Codes read as this program: DW4421.

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.
DW4421 (Daewon Pharmaceutical): development program | ClinicalTrials.gg